Silverfin false false 30/04/2026 01/05/2025 30/04/2026 L R Pollard 12/03/2026 D S Rose 05/03/2007 E C Rose 12/03/2026 S O Rose 12/03/2026 11 August 2026 The principal activity of the Company during the financial year was that of a retail pharmacy. 06138376 2026-04-30 06138376 bus:Director1 2026-04-30 06138376 bus:Director2 2026-04-30 06138376 bus:Director3 2026-04-30 06138376 bus:Director4 2026-04-30 06138376 2025-04-30 06138376 core:CurrentFinancialInstruments 2026-04-30 06138376 core:CurrentFinancialInstruments 2025-04-30 06138376 core:ShareCapital 2026-04-30 06138376 core:ShareCapital 2025-04-30 06138376 core:RetainedEarningsAccumulatedLosses 2026-04-30 06138376 core:RetainedEarningsAccumulatedLosses 2025-04-30 06138376 core:Goodwill 2025-04-30 06138376 core:Goodwill 2026-04-30 06138376 core:LeaseholdImprovements 2025-04-30 06138376 core:FurnitureFittings 2025-04-30 06138376 core:LeaseholdImprovements 2026-04-30 06138376 core:FurnitureFittings 2026-04-30 06138376 2025-05-01 2026-04-30 06138376 bus:FilletedAccounts 2025-05-01 2026-04-30 06138376 bus:SmallEntities 2025-05-01 2026-04-30 06138376 bus:AuditExemptWithAccountantsReport 2025-05-01 2026-04-30 06138376 bus:PrivateLimitedCompanyLtd 2025-05-01 2026-04-30 06138376 bus:Director1 2025-05-01 2026-04-30 06138376 bus:Director2 2025-05-01 2026-04-30 06138376 bus:Director3 2025-05-01 2026-04-30 06138376 bus:Director4 2025-05-01 2026-04-30 06138376 core:Goodwill core:TopRangeValue 2025-05-01 2026-04-30 06138376 core:Goodwill 2025-05-01 2026-04-30 06138376 core:LeaseholdImprovements core:TopRangeValue 2025-05-01 2026-04-30 06138376 core:FurnitureFittings core:TopRangeValue 2025-05-01 2026-04-30 06138376 2024-05-01 2025-04-30 06138376 core:LeaseholdImprovements 2025-05-01 2026-04-30 06138376 core:FurnitureFittings 2025-05-01 2026-04-30 iso4217:GBP xbrli:pure

Company No: 06138376 (England and Wales)

# ROSEPHARM LTD

### Unaudited Financial Statements
For the financial year ended 30 April 2026
Pages for filing with the registrar

ROSEPHARM LTD

## Unaudited Financial Statements

For the financial year ended 30 April 2026

Contents

ROSEPHARM LTD

## BALANCE SHEET

As at 30 April 2026
ROSEPHARM LTD

## BALANCE SHEET (continued)

As at 30 April 2026

| Note | 2026 |  | 2025
|  | £ |  | £
Fixed assets |  |  |  |
Intangible assets | 3 | 0 |  | 23,311
Tangible assets | 4 | 1,530 |  | 2,291
|  | 1,530 |  | 25,602
Current assets |  |  |  |
Stocks |  | 33,067 |  | 38,133
Debtors | 5 | 369,198 |  | 208,041
Cash at bank and in hand |  | 44,599 |  | 100,931
|  | 446,864 |  | 347,105
Creditors: amounts falling due within one year | 6 | ( 305,510) |  | ( 229,693)
Net current assets |  | 141,354 |  | 117,412
Total assets less current liabilities |  | 142,884 |  | 143,014
Provision for liabilities | 7 | ( 153) |  | ( 573)
Net assets |  | 142,731 |  | 142,441
Capital and reserves |  |  |  |
Called-up share capital |  | 100 |  | 100
Profit and loss account |  | 142,631 |  | 142,341
Total shareholder's funds |  | 142,731 |  | 142,441

For the financial year ending 30 April 2026 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The member has not required the Company to obtain an audit of its financial statements for the financial year in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements; and
- These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and a copy of the Profit and Loss Account has not been delivered.

The financial statements of Rosepharm Ltd (registered number: 06138376) were approved and authorised for issue by the Board of Directors on 11 August 2026. They were signed on its behalf by:

D S Rose Director |

ROSEPHARM LTD

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 30 April 2026
ROSEPHARM LTD

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 30 April 2026

##### 1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

##### General information and basis of accounting

Rosepharm Ltd (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Albert Goodman, Lupin Way, Yeovil, BA22 8WW, United Kingdom. The principal place of business is Marnhull Pharmacy, Church Hill, Marnhull, Sturminster Newton, Dorset, DT10 1PU, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

##### Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

##### Employee benefits

Defined contribution schemes
The Company operates a defined contribution scheme. The amount charged to the Profit and Loss Account in respect of pension costs and other post-retirement benefits is the contributions payable in the financial year. Differences between contributions payable in the financial year and contributions actually paid are included as either accruals or prepayments in the Balance Sheet.

##### Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date. Tax is recognised in the profit and loss account, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.
Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date that are expected to apply when the timing differences reverse. Deferred tax assets and liabilities are not discounted.
Deferred tax liabilities are presented within provisions for liabilities on the balance sheet.

##### Intangible assets

Intangible assets are stated at cost or valuation, net of amortisation and any provision for impairment. Amortisation is provided on all intangible assets at rates to write off the cost or valuation of each asset over its expected useful life as follows:

Goodwill | 10 years straight line

###### Goodwill

Goodwill arises on business combinations and represents any excess of consideration given over the fair value of the identifiable assets and liabilities acquired. Goodwill is initially recognised as an intangible asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

##### Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Leasehold improvements | 9 years straight line
Fixtures and fittings | 4 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

##### Leases

The Company as lessee
Rentals under operating leases are charged on a straight-line basis over the lease term, even if the payments are not made on such a basis. Benefits received and receivable as an incentive to sign an operating lease are similarly spread on a straight-line basis over the lease term.

##### Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to sell, which is equivalent to the net realisable value. Stocks is comprised of finished goods for resale, stated at the lower of cost and estimated selling price less costs to sell, which is equivalent to the net realisable value. Cost is calculated using the FIFO (first-in, first-out) method. Provision is made for obsolete, slow-moving or defective items where appropriate.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

##### Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts, except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

##### Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

##### Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

##### Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.
Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Equity instruments
Equity instruments issued by the Company are recorded at the fair value of cash or other resources received or receivable, net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the Company.

Loans and borrowings
Loans and borrowings are initially recognised at the transaction price including transaction costs. Subsequently, they are measured at amortised cost using the effective interest rate method, less impairment. Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

##### Ordinary share capital

The ordinary share capital of the Company is presented as equity.

#### 2. Employees

| 2026 |  | 2025
| Number |  | Number
Monthly average number of persons employed by the Company during the year, including directors | 11 |  | 11

#### 3. Intangible assets

| Goodwill |  | Total
| £ |  | £
Cost |  |  |
At 01 May 2025 | 423,785 |  | 423,785
At 30 April 2026 | 423,785 |  | 423,785
Accumulated amortisation |  |  |
At 01 May 2025 | 400,474 |  | 400,474
Charge for the financial year | 23,311 |  | 23,311
At 30 April 2026 | 423,785 |  | 423,785
Net book value |  |  |
At 30 April 2026 | 0 |  | 0
At 30 April 2025 | 23,311 |  | 23,311

#### 4. Tangible assets

| Leasehold improve- ments |  | Fixtures and fittings |  | Total
| £ |  | £ |  | £
Cost |  |  |  |  |
At 01 May 2025 | 7,990 |  | 13,900 |  | 21,890
Additions | 0 |  | 525 |  | 525
Disposals | 0 |  | ( 6,234) |  | ( 6,234)
At 30 April 2026 | 7,990 |  | 8,191 |  | 16,181
Accumulated depreciation |  |  |  |  |
At 01 May 2025 | 6,616 |  | 12,983 |  | 19,599
Charge for the financial year | 458 |  | 236 |  | 694
Disposals | 0 |  | ( 5,642) |  | ( 5,642)
At 30 April 2026 | 7,074 |  | 7,577 |  | 14,651
Net book value |  |  |  |  |
At 30 April 2026 | 916 |  | 614 |  | 1,530
At 30 April 2025 | 1,374 |  | 917 |  | 2,291

#### 5. Debtors

| 2026 |  | 2025
| £ |  | £
Trade debtors | 130,885 |  | 109,766
Amounts owed by directors | 0 |  | 29,707
Prepayments | 2,246 |  | 2,247
VAT recoverable | 35,439 |  | 15,602
Other debtors | 200,628 |  | 50,719
| 369,198 |  | 208,041

Within other debtors, there is an amount of £200,000 relating to pension contributions paid during the financial period which were reimbursed after the year end.

#### 6. Creditors: amounts falling due within one year

| 2026 |  | 2025
| £ |  | £
Trade creditors | 128,111 |  | 193,583
Amounts owed to directors | 144,395 |  | 0
Accruals | 5,225 |  | 5,020
Corporation tax | 18,231 |  | 22,366
Other taxation and social security | 7,585 |  | 6,891
Other creditors | 1,963 |  | 1,833
| 305,510 |  | 229,693

#### 7. Provision for liabilities

| 2026 |  | 2025
| £ |  | £
Deferred tax | 153 |  | 573

#### 8. Related party transactions

Transactions with the entity's directors

Advances

The Director's loan account is repayable on demand and interest is charged on overdrawn balances exceeding £10,000 at the official HMRC rates.
At 1 May 2025, the balance owed by the director was £29,707. During the year, £35,064 was advanced to the director, and £64,771 was repaid by the director. At 30 April 2026, the balance owed by the director was £nil.
At 1 May 2024, the balance owed by the director was £183,070. During the year, £125,039 was advanced to the director, and £278,402 was repaid by the director. At 30 April 2025, the balance owed by the director was £29,707.